Want to see FR:DIM full AI Analyst Report?
Top Page
Sartorius Stedim Biotech
(DIM)
Select Model
Select Model
Rating:62Neutral
Price Target:
€232.00
▲(17.35% Upside)
Action:Reiterated
Date:10/08/26
The score is driven primarily by improving fundamentals (strong TTM revenue rebound and better leverage) and supportive technical momentum (price above major moving averages with positive MACD). These positives are materially offset by expensive valuation (high P/E) and still-recovering profitability and cash-flow conversion.
Positive Factors
Revenue Recovery
The sharp TTM revenue rebound indicates that demand and operating activity are recovering across Sartorius Stedim Biotech’s bioprocessing portfolio. Sustained revenue improvement can support better fixed-cost absorption, strengthen customer engagement, and provide a foundation for renewed earnings growth.
Negative Factors
Depressed Profitability
Although revenue has recovered, net profitability remains far below its prior peak, showing that volume growth has not yet translated into full earnings normalization. Persistently lower margins could constrain internal investment, reduce operating resilience, and leave results more sensitive to execution challenges.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The sharp TTM revenue rebound indicates that demand and operating activity are recovering across Sartorius Stedim Biotech’s bioprocessing portfolio. Sustained revenue improvement can support better fixed-cost absorption, strengthen customer engagement, and provide a foundation for renewed earnings growth.
Read all positive factors
Sartorius Stedim Biotech (DIM) vs. iShares MSCI France ETF (EWQ)
Market Cap
€20.71B
Dividend Yield0.32%
Average Volume (3M)97.39K
Price to Earnings (P/E)70.5
Beta (1Y)1.40
Revenue Growth3.76%
EPS Growth29.94%
CountryFR
Employees10,477
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. Volume107,859
30 Day Avg. Volume97,393
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€238.83Price Target Upside20.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5.02
Revenue Forecast (FY)€3.13B
Sartorius Stedim Biotech Business Overview & Revenue Model
Company Description
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental component...
How the Company Makes Money
Sartorius Stedim Biotech makes money by selling a mix of recurring consumables and higher-value capital equipment and systems to customers involved in the development and manufacture of biologic medicines. A major component of its revenue model is...
Sartorius Stedim Biotech Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
66
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.01B | 2.97B | 2.78B | 2.78B | 3.49B | 2.89B |
| Gross Profit | 1.35B | 1.35B | 1.21B | 1.23B | 1.82B | 1.55B |
| EBITDA | 886.60M | 867.10M | 670.50M | 755.70M | 1.33B | 811.96M |
| Net Income | 292.60M | 265.60M | 175.10M | 309.70M | 876.10M | 414.40M |
Balance Sheet | ||||||
| Total Assets | 7.92B | 8.02B | 8.26B | 7.74B | 5.07B | 3.95B |
| Cash, Cash Equivalents and Short-Term Investments | 203.90M | 434.20M | 688.80M | 126.10M | 133.00M | 237.35M |
| Total Debt | 2.40B | 2.60B | 2.87B | 3.68B | 1.14B | 625.52M |
| Total Liabilities | 3.67B | 3.89B | 4.23B | 5.07B | 2.55B | 2.22B |
| Stockholders Equity | 4.24B | 4.09B | 3.99B | 2.64B | 2.45B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | 220.70M | 145.40M | 475.30M | 156.10M | 181.70M | 371.98M |
| Operating Cash Flow | 615.10M | 538.60M | 815.10M | 629.70M | 612.30M | 695.97M |
| Investing Cash Flow | -468.80M | -397.70M | -340.00M | -2.72B | -957.50M | -465.23M |
| Financing Cash Flow | -643.20M | -389.20M | 84.90M | 1.99B | 220.70M | -69.27M |
Sartorius Stedim Biotech Technical Analysis
Positive
197.70
Price Trends
194.68
Positive
185.18
Positive
182.00
Positive
Market Momentum
5.70
Positive
57.84
Neutral
43.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Positive. The current price of 197.7 is below the 20-day moving average (MA) of 206.51, above the 50-day MA of 194.68, and above the 200-day MA of 182.00, indicating a bullish trend. The MACD of 5.70 indicates Positive momentum. The RSI at 57.84 is Neutral, neither overbought nor oversold. The STOCH value of 43.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:DIM.
Sartorius Stedim Biotech Peers Comparison
UnderperformOutperform
Sector (55)
FR:DIM
Sartorius Stedim Biotech
212.80
26.46
14.20%
FR:BIM
bioMerieux
83.20
-24.62
-22.83%
FR:ERF
Eurofins Scientific
77.12
16.10
26.39%
Sartorius Stedim Biotech Corporate Events
Sartorius Stedim Biotech Updates Share Capital and Voting Rights
Oct 1, 2026
Sartorius Stedim Biotech has reported that its share capital consists of 97,330,405 shares as of 30 September 2026. The company also disclosed 164,770,938 theoretical voting rights and 164,752,145 net voting rights, in line with French regulatory ...
Sartorius Stedim Biotech Updates Share Capital and Voting Rights Structure
Sep 3, 2026
Sartorius Stedim Biotech has reported the latest composition of its share capital as of 31 August 2026, disclosing a total of 97,330,405 shares outstanding. The company also detailed 164,770,938 theoretical voting rights and 164,733,033 net voting...
Sartorius Stedim Biotech Updates Market on Share Capital and Voting Rights
Aug 4, 2026
Sartorius Stedim Biotech has reported the latest composition of its share capital and voting rights, as required under French commercial law and AMF regulations, for the date of 31 July 2026. The company disclosed that its share capital consists o...
Sartorius Stedim Biotech Delivers H1 Growth and Confirms 2026 Outlook
Jul 23, 2026
Sartorius Stedim Biotech reported first-half 2026 sales of €1.53 billion, with operating sales up 8% at constant exchange rates, driven mainly by recurring consumables and a return to slight growth in bioprocess equipment. Underlying EBITDA ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.